Cancer: a new mRNA vaccine eliminates tumors and prevents reoffending in mice

Cancer: a new mRNA vaccine eliminates tumors and prevents reoffending in mice

Despite the increased interest in cancer vaccine research in recent years, it has proved difficult to develop vaccines. Using lipid nanoparticles against the lymphatic system, researchers at the Tufts Engineering School believe that they have developed an effective MRNA vaccine against cancer. The vaccine completely destroyed the tumor in 40% of the mice and prevented it from reappearing.

On the one hand, it was reported that the information RNA vaccines currently used in clinical trials caused side effects in the liver, which could be caused by unwanted antigen expression in that organ; although these antigens could still give an immune response, the risk of inflammation and liver damage remained.

On the other hand, "" said Jinjin Chen, a post-doctoral researcher from Tufts University and co-author of ."

The MRNA vaccine presented in the study is aimed specifically at the lymphatic system, where B-, T-cells and other immune system cells "train" to combat infection, and it is in the lymphatic system that immunity to cancer antigen is acquired.

Like Pfizer and Moderna's COVID-19 vaccines, this potential cancer vaccine also delivers MRNA in tiny lipid bubbles called "lipid nanoparticles." They then merge with body cells, reaching the lymph system, allowing them to decipher MRNA and produce viral antigens — small fragments of the virus — that activate the immune system.

"", said Qiaobin Xu, a professor of biomedical engineering and co-author of the study, Targesting is achieved by modifying the chemical structure of lipids in bubbles after subcutaneous introduction to mice.

"", the authors report: Mice with metastatic melanoma, treated with lymphocymic vaccine, experienced significant tumor suppression and complete remission in 40 per cent of cases, when the vaccine was combined with other treatments to prevent immune responses from being controlled by cancer cells, no recurrences were observed for a long time.

In addition, all mice that had reached full remission prevented the formation of new tumors when they were subsequently introduced into metastatic tumor cells, indicating that the cancer vaccine had created an excellent immune memory.